Nalmefene to prevent epidural narcotic side effects in pediatric patients: A pharmacokinetic and safety study

David A. Rosen, John L. Morris, Kathleen R. Rosen, Elizabeth R. Nelson, Robert Steelman, Robert A. Gustafson, Jeffrey A. Wilhelm, Cheng T. Chang, Jeffrey W. Thackara, Reginald F. Frye

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Study Objective. To determine the pharmacokinetics and preliminary efficacy of nalmefene in children in preventing epidural-induced narcotic side effects. Design. Double-blind, placebo-controlled study. Setting. University-affiliated children's hospital. Patients. Thirty-four children (aged 2-12 yrs) undergoing cardiothoracic surgery with epidural anesthesia. Interventions. Patients were randomized to receive intravenous bolus nalmefene 1 μg/kg or placebo. Measurements and Main Results. Six blood samples (one before nalmefene administration and five from 13 randomly designated time points) from each patient were assayed to determine plasma nalmefene concentrations. Patients were assessed for pain, nausea, vomiting, and urinary retention for 24 hours after administration. Concentration-time data were analyzed by a limited sampling strategy with adult pharmacokinetic parameters used as Bayesian priors. A two-compartment, first-order model was fitted to the data using ADAPT II. Pharmacokinetic parameter estimates in these patients were similar to values reported in adults. The initial disposition half-life (t(1/2α)) was 0.36 ± 0.11 hour, the terminal elimination half-life (t(1/2β)) 8.7 ± 2.3 hours, clearance 0.729 ± 0.172 L/kg/hr, and steady-state volume of distribution 7.21 ± 2.49 L/kg. Ability to prevent epidural narcotic-induced side effects could not be documented at the 1-μg/kg dose. No statistically significant differences were noted between study and placebo groups with regard to pain, nausea, vomiting, or urinary retention. Conclusion. Nalmefene has similar pharmacokinetics in children as in adults. It was administered safely to these patients and did not produce unmanageable pain.

Original languageEnglish (US)
Pages (from-to)745-749
Number of pages5
JournalPharmacotherapy
Volume20
Issue number7 I
StatePublished - 2000
Externally publishedYes

Fingerprint

Narcotics
Pharmacokinetics
Pediatrics
Safety
Urinary Retention
Placebos
Pain
Nausea
Vomiting
Half-Life
Aptitude
Epidural Anesthesia
nalmefene

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Rosen, D. A., Morris, J. L., Rosen, K. R., Nelson, E. R., Steelman, R., Gustafson, R. A., ... Frye, R. F. (2000). Nalmefene to prevent epidural narcotic side effects in pediatric patients: A pharmacokinetic and safety study. Pharmacotherapy, 20(7 I), 745-749.

Nalmefene to prevent epidural narcotic side effects in pediatric patients : A pharmacokinetic and safety study. / Rosen, David A.; Morris, John L.; Rosen, Kathleen R.; Nelson, Elizabeth R.; Steelman, Robert; Gustafson, Robert A.; Wilhelm, Jeffrey A.; Chang, Cheng T.; Thackara, Jeffrey W.; Frye, Reginald F.

In: Pharmacotherapy, Vol. 20, No. 7 I, 2000, p. 745-749.

Research output: Contribution to journalArticle

Rosen, DA, Morris, JL, Rosen, KR, Nelson, ER, Steelman, R, Gustafson, RA, Wilhelm, JA, Chang, CT, Thackara, JW & Frye, RF 2000, 'Nalmefene to prevent epidural narcotic side effects in pediatric patients: A pharmacokinetic and safety study', Pharmacotherapy, vol. 20, no. 7 I, pp. 745-749.
Rosen, David A. ; Morris, John L. ; Rosen, Kathleen R. ; Nelson, Elizabeth R. ; Steelman, Robert ; Gustafson, Robert A. ; Wilhelm, Jeffrey A. ; Chang, Cheng T. ; Thackara, Jeffrey W. ; Frye, Reginald F. / Nalmefene to prevent epidural narcotic side effects in pediatric patients : A pharmacokinetic and safety study. In: Pharmacotherapy. 2000 ; Vol. 20, No. 7 I. pp. 745-749.
@article{3e31099d1f91458cb482ba6858b16f73,
title = "Nalmefene to prevent epidural narcotic side effects in pediatric patients: A pharmacokinetic and safety study",
abstract = "Study Objective. To determine the pharmacokinetics and preliminary efficacy of nalmefene in children in preventing epidural-induced narcotic side effects. Design. Double-blind, placebo-controlled study. Setting. University-affiliated children's hospital. Patients. Thirty-four children (aged 2-12 yrs) undergoing cardiothoracic surgery with epidural anesthesia. Interventions. Patients were randomized to receive intravenous bolus nalmefene 1 μg/kg or placebo. Measurements and Main Results. Six blood samples (one before nalmefene administration and five from 13 randomly designated time points) from each patient were assayed to determine plasma nalmefene concentrations. Patients were assessed for pain, nausea, vomiting, and urinary retention for 24 hours after administration. Concentration-time data were analyzed by a limited sampling strategy with adult pharmacokinetic parameters used as Bayesian priors. A two-compartment, first-order model was fitted to the data using ADAPT II. Pharmacokinetic parameter estimates in these patients were similar to values reported in adults. The initial disposition half-life (t(1/2α)) was 0.36 ± 0.11 hour, the terminal elimination half-life (t(1/2β)) 8.7 ± 2.3 hours, clearance 0.729 ± 0.172 L/kg/hr, and steady-state volume of distribution 7.21 ± 2.49 L/kg. Ability to prevent epidural narcotic-induced side effects could not be documented at the 1-μg/kg dose. No statistically significant differences were noted between study and placebo groups with regard to pain, nausea, vomiting, or urinary retention. Conclusion. Nalmefene has similar pharmacokinetics in children as in adults. It was administered safely to these patients and did not produce unmanageable pain.",
author = "Rosen, {David A.} and Morris, {John L.} and Rosen, {Kathleen R.} and Nelson, {Elizabeth R.} and Robert Steelman and Gustafson, {Robert A.} and Wilhelm, {Jeffrey A.} and Chang, {Cheng T.} and Thackara, {Jeffrey W.} and Frye, {Reginald F.}",
year = "2000",
language = "English (US)",
volume = "20",
pages = "745--749",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "7 I",

}

TY - JOUR

T1 - Nalmefene to prevent epidural narcotic side effects in pediatric patients

T2 - A pharmacokinetic and safety study

AU - Rosen, David A.

AU - Morris, John L.

AU - Rosen, Kathleen R.

AU - Nelson, Elizabeth R.

AU - Steelman, Robert

AU - Gustafson, Robert A.

AU - Wilhelm, Jeffrey A.

AU - Chang, Cheng T.

AU - Thackara, Jeffrey W.

AU - Frye, Reginald F.

PY - 2000

Y1 - 2000

N2 - Study Objective. To determine the pharmacokinetics and preliminary efficacy of nalmefene in children in preventing epidural-induced narcotic side effects. Design. Double-blind, placebo-controlled study. Setting. University-affiliated children's hospital. Patients. Thirty-four children (aged 2-12 yrs) undergoing cardiothoracic surgery with epidural anesthesia. Interventions. Patients were randomized to receive intravenous bolus nalmefene 1 μg/kg or placebo. Measurements and Main Results. Six blood samples (one before nalmefene administration and five from 13 randomly designated time points) from each patient were assayed to determine plasma nalmefene concentrations. Patients were assessed for pain, nausea, vomiting, and urinary retention for 24 hours after administration. Concentration-time data were analyzed by a limited sampling strategy with adult pharmacokinetic parameters used as Bayesian priors. A two-compartment, first-order model was fitted to the data using ADAPT II. Pharmacokinetic parameter estimates in these patients were similar to values reported in adults. The initial disposition half-life (t(1/2α)) was 0.36 ± 0.11 hour, the terminal elimination half-life (t(1/2β)) 8.7 ± 2.3 hours, clearance 0.729 ± 0.172 L/kg/hr, and steady-state volume of distribution 7.21 ± 2.49 L/kg. Ability to prevent epidural narcotic-induced side effects could not be documented at the 1-μg/kg dose. No statistically significant differences were noted between study and placebo groups with regard to pain, nausea, vomiting, or urinary retention. Conclusion. Nalmefene has similar pharmacokinetics in children as in adults. It was administered safely to these patients and did not produce unmanageable pain.

AB - Study Objective. To determine the pharmacokinetics and preliminary efficacy of nalmefene in children in preventing epidural-induced narcotic side effects. Design. Double-blind, placebo-controlled study. Setting. University-affiliated children's hospital. Patients. Thirty-four children (aged 2-12 yrs) undergoing cardiothoracic surgery with epidural anesthesia. Interventions. Patients were randomized to receive intravenous bolus nalmefene 1 μg/kg or placebo. Measurements and Main Results. Six blood samples (one before nalmefene administration and five from 13 randomly designated time points) from each patient were assayed to determine plasma nalmefene concentrations. Patients were assessed for pain, nausea, vomiting, and urinary retention for 24 hours after administration. Concentration-time data were analyzed by a limited sampling strategy with adult pharmacokinetic parameters used as Bayesian priors. A two-compartment, first-order model was fitted to the data using ADAPT II. Pharmacokinetic parameter estimates in these patients were similar to values reported in adults. The initial disposition half-life (t(1/2α)) was 0.36 ± 0.11 hour, the terminal elimination half-life (t(1/2β)) 8.7 ± 2.3 hours, clearance 0.729 ± 0.172 L/kg/hr, and steady-state volume of distribution 7.21 ± 2.49 L/kg. Ability to prevent epidural narcotic-induced side effects could not be documented at the 1-μg/kg dose. No statistically significant differences were noted between study and placebo groups with regard to pain, nausea, vomiting, or urinary retention. Conclusion. Nalmefene has similar pharmacokinetics in children as in adults. It was administered safely to these patients and did not produce unmanageable pain.

UR - http://www.scopus.com/inward/record.url?scp=0033922920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033922920&partnerID=8YFLogxK

M3 - Article

C2 - 10907964

AN - SCOPUS:0033922920

VL - 20

SP - 745

EP - 749

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 7 I

ER -